Danish Drugmaker LEO Pharma Secures Approval in China for Eczema Cream

Danish dermatology company LEO Pharma has received drug approval in China.

China's National Medical Products Administration approved its new cream, Anzupgo.

The topical cream treats adults with moderate to severe chronic hand eczema.

It is meant for patients who cannot use standard steroid creams.

The approval follows successful Phase 3 clinical trials across medical centers in China.

Peking University People's Hospital led the main trial in China.

The study showed significant skin improvements after 16 weeks of twice-daily treatment.

Chronic hand eczema causes severe itching, pain, and skin cracking on hands.

Before this decision, China had no treatments specifically made for chronic hand eczema.

The condition affects daily activities for roughly 70 percent of severe cases.

Anzupgo is already approved in the European Union and several other countries.

LEO Pharma stated that China is a key growth market for its treatments.

(Source: BioSpace / LEO Pharma)